subject: Non-hodgkins Lymphoma (nhl) - Pipeline Assessment And Market Forecasts To 2017 Aarkstore Enterpri [print this page] Aarkstore announce a new report "Non-Hodgkins Lymphoma (NHL) - Pipeline Assessment and Market Forecasts to 2017 " through its vast collection of market research report.
Non-Hodgkins Lymphoma (NHL) - Pipeline Assessment and Market Forecasts to 2017 report is an essential source of information and analysis on the global NHL market. The report identifies the key trends shaping and driving the global NHL market.
The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global NHL sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by a team of industry experts.
We estimated the global Non-Hodgkins Lymphoma (NHL) market to be worth $6.5 billion in 2009. It is forecast to grow at a compound annual growth rate (CAGR) of 7.74% annually over the next eight years to reach $11.9 billion by 2017. This growth can be primarily attributed to increased competition among the existing products, the release of new and enhanced treatment options, and the development of safer and more efficacious therapies. The NHL market growth will be further supported by the increased uptake of chemotherapy regimens, monoclonal antibodies and biologics. In 2009, Genentech Inc. (Roche), with its key drug Rituxan, was the leading player in the global NHL market. In 2009, Rituxan played a key role accounting to more than 80% share in the global NHL market. Pharmaceuticals and biopharmaceutical companies are under the way in reorganizing their NHL pipeline with combination therapies. There are six approved drugs in 2008, and two new drugs were approved by FDA in the first quarter of 2009. NHL pipeline is strong with 264 drugs under different stages of clinical development. Drugs that are studied with Rituxan either belong to the new mechanism of action or to the existing/old mechanism of action. Combination therapies in clinical studies projected to be more efficacious and safer than monotherapies alone. In future, the NHL market is driven by combination therapies, monoclonal antibodies, biologics, and vaccines. We analyzed that the global NHL market is moderately served with current product options with significant scope available to new entrants that would capture value from underserved segments.
We analyze that the global NHL market would double its revenues by 2017. In 2009, Genentech, Inc. accounted to be the NHL market leader with a share of more than 80%, which was contributed by its key drug Rituxan. Forthcoming monotherapies and combination therapies would much more satisfy NHL patients with safer drug profiles. The competitive landscape is populated by eight major products, of which two drugs were launched in the first half of 2009. All these drugs were moderately successful in increasing the survival rate of patients with NHL. However, companies like GlaxoSmithKline plc. (GSK), Biogen Idec, Genzyme Corporation, Genitope Corporation, Hana Biosciences, Cell Therapeutics, Inc., Millennium Pharmaceuticals, Inc. and Novartis AG, Pfizer Inc. / Wyeth having some of the most technologically advanced products in their pipeline, are expected to attract most of the investors attention. The global NHL market is expected to see intense competition in the future.
Scope
The report analyzes market opportunities and challenges for the global NHL market. Its scope includes
- Annualized global NHL market revenues data from 2001 to 2009, forecast forward for eight years to 2017.
- Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data provides a split across different phases, mechanism of actions being developed and emerging trends. Key classes of mechanism of action include CD targetors, anti-CD20 monoclonal antibodies, antineoplastic agents, histone deacetylase inhibitors, B-cell lymphoma 2 inhibitors, CD22 antigens, anti-angiogenesis inhibitors, DNA synthesis inhibitors, syk kinase inhibitors and proteasome inhibitors.
- Analysis of the current and future market competition in the global NHL market. Key market players covered are Genentech Inc., GSK, Biogen Idec, Genzyme Corporation, Cell Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis AG, Pfizer Inc. / Wyeth, and Genitope Corporation.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with NHL
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global NHL market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global NHL market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- Whats the next big thing in the global NHL market landscape? Identify, understand and capitalize.
